136 related articles for article (PubMed ID: 36598701)
21. DLAT as a Cuproptosis Promoter and a Molecular Target of Elesclomol in Hepatocellular Carcinoma.
Gao F; Yuan Y; Ding Y; Li PY; Chang Y; He XX
Curr Med Sci; 2023 Jun; 43(3):526-538. PubMed ID: 37286711
[TBL] [Abstract][Full Text] [Related]
22. The molecular mechanisms of cuproptosis and its relevance to cardiovascular disease.
Wang D; Tian Z; Zhang P; Zhen L; Meng Q; Sun B; Xu X; Jia T; Li S
Biomed Pharmacother; 2023 Jul; 163():114830. PubMed ID: 37150036
[TBL] [Abstract][Full Text] [Related]
23. Ferroptosis inducers enhanced cuproptosis induced by copper ionophores in primary liver cancer.
Wang W; Lu K; Jiang X; Wei Q; Zhu L; Wang X; Jin H; Feng L
J Exp Clin Cancer Res; 2023 Jun; 42(1):142. PubMed ID: 37277863
[TBL] [Abstract][Full Text] [Related]
24. Cuproptosis Induced by ROS Responsive Nanoparticles with Elesclomol and Copper Combined with αPD-L1 for Enhanced Cancer Immunotherapy.
Guo B; Yang F; Zhang L; Zhao Q; Wang W; Yin L; Chen D; Wang M; Han S; Xiao H; Xing N
Adv Mater; 2023 Jun; 35(22):e2212267. PubMed ID: 36916030
[TBL] [Abstract][Full Text] [Related]
25. Cuproptosis: p53-regulated metabolic cell death?
Xiong C; Ling H; Hao Q; Zhou X
Cell Death Differ; 2023 Apr; 30(4):876-884. PubMed ID: 36755067
[TBL] [Abstract][Full Text] [Related]
26. ATF3/SPI1/SLC31A1 Signaling Promotes Cuproptosis Induced by Advanced Glycosylation End Products in Diabetic Myocardial Injury.
Huo S; Wang Q; Shi W; Peng L; Jiang Y; Zhu M; Guo J; Peng D; Wang M; Men L; Huang B; Lv J; Lin L
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36675183
[TBL] [Abstract][Full Text] [Related]
27. A novel cuproptosis-related prognostic gene signature and validation of differential expression in hepatocellular carcinoma.
Li Y; Zeng X
Front Pharmacol; 2022; 13():1081952. PubMed ID: 36703728
[No Abstract] [Full Text] [Related]
28. Cuproptosis illustrates tumor micro-environment features and predicts prostate cancer therapeutic sensitivity and prognosis.
Cheng B; Tang C; Xie J; Zhou Q; Luo T; Wang Q; Huang H
Life Sci; 2023 Jul; 325():121659. PubMed ID: 37011878
[TBL] [Abstract][Full Text] [Related]
29. The Role of Ferroptosis and Cuproptosis in Curcumin against Hepatocellular Carcinoma.
Liu Z; Ma H; Lai Z
Molecules; 2023 Feb; 28(4):. PubMed ID: 36838613
[TBL] [Abstract][Full Text] [Related]
30. Leveraging a cuproptosis-based signature to predict the prognosis and drug sensitivity of cutaneous melanoma.
Liu D; Yang F; Zhang T; Mao R
J Transl Med; 2023 Jan; 21(1):57. PubMed ID: 36717900
[TBL] [Abstract][Full Text] [Related]
31. 4-Octyl itaconate inhibits aerobic glycolysis by targeting GAPDH to promote cuproptosis in colorectal cancer.
Yang W; Wang Y; Huang Y; Yu J; Wang T; Li C; Yang L; Zhang P; Shi L; Yin Y; Tao K; Li R
Biomed Pharmacother; 2023 Mar; 159():114301. PubMed ID: 36706634
[TBL] [Abstract][Full Text] [Related]
32. Copper and cuproptosis-related genes in hepatocellular carcinoma: therapeutic biomarkers targeting tumor immune microenvironment and immune checkpoints.
Wang X; Chen D; Shi Y; Luo J; Zhang Y; Yuan X; Zhang C; Shu H; Yu W; Tian J
Front Immunol; 2023; 14():1123231. PubMed ID: 37153542
[TBL] [Abstract][Full Text] [Related]
33. A cuproptosis-related lncRNA signature to predict prognosis and immune microenvironment of colon adenocarcinoma.
Li D; Qu G; Ling S; Sun Y; Cui Y; Yang Y; Cao X
Sci Rep; 2023 Apr; 13(1):6284. PubMed ID: 37072493
[TBL] [Abstract][Full Text] [Related]
34. Prognostic signature construction and immunotherapy response analysis for Uterine Corpus Endometrial Carcinoma based on cuproptosis-related lncRNAs.
Zhang X; Ye Z; Xiao G; He T
Comput Biol Med; 2023 Jun; 159():106905. PubMed ID: 37060773
[TBL] [Abstract][Full Text] [Related]
35. Machine learning algorithm to construct cuproptosis- and immune-related prognosis prediction model for colon cancer.
Huang YY; Bao TY; Huang XQ; Lan QW; Huang ZM; Chen YH; Hu ZD; Guo XG
World J Gastrointest Oncol; 2023 Mar; 15(3):372-388. PubMed ID: 37009317
[TBL] [Abstract][Full Text] [Related]
36. Six immune-related promising biomarkers may promote hepatocellular carcinoma prognosis: a bioinformatics analysis and experimental validation.
Lin XH; Li DP; Liu ZY; Zhang S; Tang WQ; Chen RX; Weng SQ; Tseng YJ; Xue RY; Dong L
Cancer Cell Int; 2023 Mar; 23(1):52. PubMed ID: 36959615
[TBL] [Abstract][Full Text] [Related]
37. The implications and prospect of cuproptosis-related genes and copper transporters in cancer progression.
Zhao Q; Qi T
Front Oncol; 2023; 13():1117164. PubMed ID: 36925927
[TBL] [Abstract][Full Text] [Related]
38. Construction and validation of a cuproptosis-related prognostic model for glioblastoma.
Zhang B; Xie L; Liu J; Liu A; He M
Front Immunol; 2023; 14():1082974. PubMed ID: 36814929
[TBL] [Abstract][Full Text] [Related]
39. Copper homeostasis and copper-induced cell death in the pathogenesis of cardiovascular disease and therapeutic strategies.
Chen X; Cai Q; Liang R; Zhang D; Liu X; Zhang M; Xiong Y; Xu M; Liu Q; Li P; Yu P; Shi A
Cell Death Dis; 2023 Feb; 14(2):105. PubMed ID: 36774340
[TBL] [Abstract][Full Text] [Related]
40. EREG is the core onco-immunological biomarker of cuproptosis and mediates the cross-talk between VEGF and CD99 signaling in glioblastoma.
Zhou Y; Xiao D; Jiang X; Nie C
J Transl Med; 2023 Jan; 21(1):28. PubMed ID: 36647156
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
